EBOLA VACCINE MARKET ANALYSIS

Ebola Vaccine Market, By Virus Strain (Recombinant vesicular stomatitis virus-Zaire Ebola virus, Chimpanzee Adeno virus type 3-Zaire Ebola virus, and Adeno virus serotype 26- Zaire Ebola Virus) and by Geography — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Oct 2024
Code : CMI1365
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market

Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.

GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine).